Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
Type:
Grant
Filed:
August 22, 2023
Date of Patent:
January 7, 2025
Assignee:
Gilead Sciences, Inc.
Inventors:
Julie Farand, Tezcan Guney, Darryl Kato, John O. Link, James B. C. Mack, William J. Watkins
Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
Type:
Grant
Filed:
March 9, 2022
Date of Patent:
December 31, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Gediminas J. Brizgys, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Michael L. Mitchell, Scott D. Schroeder, Nathan D. Shapiro, Suzanne M. Szewczyk, James G. Taylor, Nathan E. Wright, Sheila M. Zipfel
Abstract: Compounds and methods of using said compounds, singly or in combination with additional agents, and salts or pharmaceutical compositions of said compounds for the treatment of viral infections are disclosed.
Type:
Grant
Filed:
March 11, 2024
Date of Patent:
December 31, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Mark J. Bartlett, Daniel H. Byun, Yifan Deng, Jennifer L. Cosman Ellis, Rao V. Kalla, Richard L Mackman, Dustin S. Siegel, Xianhuang Zeng
Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
Type:
Grant
Filed:
March 9, 2023
Date of Patent:
December 10, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.
Type:
Grant
Filed:
November 29, 2022
Date of Patent:
December 10, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Jinfa Du, Joshua A. Kaplan, Thorsten A. Kirschberg, Tetsuya Kobayashi, Scott E. Lazerwith, Rick Andrew Lee, Jonathan William Medley, Michael L. Mitchell, Philip Anthony Morganelli, Hyung-Jung Pyun, Sophia L. Shevick, Neil H. Squires, William J. Watkins
Abstract: The present disclosure relates salts and the crystalline forms of certain 3?,4,4?,5-tetrahydro-2H,2?H-spiro[benzo[b][1,4]oxazepine-3,1?-naphthalene] derivatives as well as pharmaceutical formulations and therapeutic uses thereof. The present disclosure also relates to preparing such salts, crystalline forms and pharmaceutical formulations.
Type:
Grant
Filed:
May 3, 2023
Date of Patent:
December 10, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
John Enquist, Michael A. Ischay, Olga V. Lapina, David W. Lin, Christopher S. Regens, David A. Siler, Eric A. Standley, Sarah E. Wortman
Abstract: The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
Type:
Grant
Filed:
May 24, 2023
Date of Patent:
November 12, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Barton W. Phillips, Doris T. Tang, Chandrasekar Venkataramani, Kin S. Yang, Anna Zagorska
Abstract: The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
Type:
Grant
Filed:
May 12, 2023
Date of Patent:
October 22, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Lan Jiang, David W. Lin, Michael L. Mitchell, Ezra Roberts, Gregg M. Schwarzwalder
Abstract: The present disclosure relates to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2, including cancer.
Type:
Grant
Filed:
December 20, 2022
Date of Patent:
October 22, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Peter A. Blomgren, Zhimin Du, Musong Kim, Rhiannon Thomas-Tran, Michael T. Tudesco, Chandrasekar Venkataramani
Abstract: Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
Type:
Grant
Filed:
November 16, 2023
Date of Patent:
October 22, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Jinfa Du, Dhanapalan Nagarathnam, Michael Joseph Sofia, Peiyuan Wang
Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.
Type:
Grant
Filed:
January 27, 2021
Date of Patent:
October 22, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Stephen E. Ammann, Gediminas J. Brizgys, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, Daniel G. Shore, Suzanne M. Szewczyk, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.
Type:
Grant
Filed:
June 5, 2023
Date of Patent:
October 22, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Anna Michelle Wagner, Scott Alan Wolckenhauer
Abstract: Phospholipid compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical formulations of said compounds for the treatment of viral infections are disclosed.
Type:
Grant
Filed:
August 16, 2022
Date of Patent:
October 15, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Byoung-Kwon Chun, Michael O. Clarke, Deeba Ensan, Rao V. Kalla, Richard L Mackman, Jagadeesh N. Manda, Devan Naduthambi, Dustin S. Siegel
Abstract: Compounds, compositions, and method useful for treating a viral infection, such as human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, are disclosed. In particular, prodrugs of phosphonamide nucleotide analogues and methods for their preparation and use as therapeutic or prophylactic agents are disclosed.
Type:
Grant
Filed:
August 5, 2021
Date of Patent:
October 8, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Daniel H. Byun, Byoung-Kwon Chun, Michael O. Clarke, Petr Jansa, Devan Naduthambi, Neil H. Squires
Abstract: The present disclosure provides pyrimidine dione compounds of Formula I and pharmaceutical compositions thereof, for treating cancer, including solid tumors either-used alone or in combination with other anti-cancer agents.
Type:
Grant
Filed:
April 29, 2021
Date of Patent:
October 8, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Mark J. Bartlett, Gregory F. Chin, Michael O. Clarke, Jennifer L. Cosman, Deeba Ensan, Bindu Goyal, Stephen Ho, Hon C. Hui, Richard L. Mackman, Michael R. Mish, Scott D. Schroeder, Nathan D. Shapiro, Dustin S. Siegel, Doris T. Tang, Hai Yang
Abstract: Disclosed herein are novel solid forms of FXR agonists. The disclosure also relates to pharmaceutical compositions containing one or more of the solid forms disclosed herein, as well as methods of using the solid forms in the treatment of conditions mediated by FXR. The disclosure also relates to methods for obtaining such solid forms.
Type:
Grant
Filed:
October 31, 2022
Date of Patent:
October 1, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Derek M. Dalton, Peter C. Fung, Nolan Griggs, Jeffrey N. Hemenway, Olga V. Lapina, Matthew M. Logan, Sean T. Neville, Bryan J. Reynolds, Hui-Wen Shih, Anna M. Wagner
Abstract: The present disclosure relates to a method of treating non-alcoholic steatohepatitis (NASH) comprising administering to a subject with NASH a combination therapy comprising semaglutide, firsocostat, and/or cilofexor.
Type:
Application
Filed:
May 24, 2024
Publication date:
September 19, 2024
Applicants:
Gilead Sciences, Inc., Novo Nordisk A/S
Inventors:
Constantine Stephen Djedjos, Bryan John McColgan, Robert Paul Myers, Gangadharan Mani Subramanian, Lene Melchiorsen, Morten Hansen
Abstract: The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
Type:
Grant
Filed:
October 3, 2023
Date of Patent:
September 17, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Stephen E. Ammann, Xinpei Cai, Eda Y. Canales, Weng K. Chang, Gregory F. Chin, Henok H. Kinfe, Jessica L. Mckinley, Michael R. Mish, Devan Naduthambi, Jason K. Perry, Kevin X. Rodriguez, Scott D. Schroeder, Christopher J. Swank, Joshua J. Van Veldhuizen
Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
Type:
Grant
Filed:
March 9, 2022
Date of Patent:
September 17, 2024
Assignee:
Gilead Sciences, Inc.
Inventors:
Gediminas J. Brizgys, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Michael L. Mitchell, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
Abstract: The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
Type:
Grant
Filed:
November 9, 2022
Date of Patent:
September 17, 2024
Assignees:
Nurix Therapeutics, Inc., Gilead Sciences, Inc.
Inventors:
John Buell, Frederick Cohen, Ryan Pemberton, Hunter P. Shunatona, Lan Wang, Mark Edward Zak